| H3K4me2 reliably defines transcription factor binding regions in different cells Y Wang, X Li, H Hu Genomics 103 (2-3), 222-228, 2014 | 106 | 2014 |
| Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10 J Abraham, AJ Montero, RC Jankowitz, MA Salkeni, JH Beumer, ... Journal of Clinical Oncology 37 (29), 2601, 2019 | 67 | 2019 |
| Transcriptional regulation of co-expressed microRNA target genes Y Wang, X Li, H Hu Genomics 98 (6), 445-452, 2011 | 61 | 2011 |
| NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel+ trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer SA Jacobs, A Robidoux, J Abraham, JM Pérez-Garcia, N La Verde, ... Breast Cancer Research 21, 1-11, 2019 | 40 | 2019 |
| MBBC: an efficient approach for metagenomic binning based on clustering Y Wang, H Hu, X Li BMC bioinformatics 16, 1-11, 2015 | 36 | 2015 |
| Prognostic cancer gene signatures share common regulatory motifs Y Wang, S Goodison, X Li, H Hu Scientific reports 7 (1), 4750, 2017 | 27 | 2017 |
| Chipmodule: systematic discovery of transcription factors and their cofactors from chip-seq data J Ding, X Cai, Y Wang, H Hu, X Li Biocomputing 2013, 320-331, 2013 | 26 | 2013 |
| Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A … SA Jacobs, JJ Lee, TJ George, JL Wade III, PJ Stella, D Wang, AR Sama, ... Clinical Cancer Research 27 (6), 1612-1622, 2021 | 18 | 2021 |
| rRNAFilter: a fast approach for ribosomal RNA read removal without a reference database Y Wang, H Hu, X Li Journal of Computational Biology 24 (4), 368-375, 2017 | 16 | 2017 |
| Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations R Pal, N Wei, N Song, S Wu, RS Kim, Y Wang, PG Gavin, PC Lucas, ... PloS one 13 (8), e0200836, 2018 | 15 | 2018 |
| MBMC: an effective markov chain approach for binning metagenomic reads from environmental shotgun sequencing projects Y Wang, H Hu, X Li Omics: a journal of integrative biology 20 (8), 470-479, 2016 | 15 | 2016 |
| Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU … KL Pogue-Geile, T Andre, N Song, C Lipchik, Y Wang, RS Kim, H Feng, ... Journal of Clinical Oncology 37 (15_suppl), 3503-3503, 2019 | 12 | 2019 |
| Motif analysis unveils the possible co-regulation of chloroplast genes and nuclear genes encoding chloroplast proteins Y Wang, J Ding, H Daniell, H Hu, X Li Plant molecular biology 80, 177-187, 2012 | 6 | 2012 |
| Validation of the NSABP/NRG oncology 8-gene trastuzumab-benefit signature in alliance/NCCTG N9831 KL Pogue-Geile, N Song, DJ Serie, Y Wang, PG Gavin, RS Kim, N Tanaka, ... JNCI Cancer Spectrum 4 (5), pkaa058, 2020 | 3 | 2020 |
| Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 KL Pogue-Geile, Y Wang, H Feng, C Lipchik, RS Kim, RS Cecchini, ... Cancer Research 79 (13_Supplement), 4064-4064, 2019 | 3 | 2019 |
| Abstract P3-10-04: the fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in … KL Pogue-Geile, Y Wang, A Srinivasan, PG Gavin, RS Kim, N Song, ... Cancer Research 79 (4_Supplement), P3-10-04-P3-10-04, 2019 | 2 | 2019 |
| Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer L Chen, Y Wang, C Cai, Y Ding, RS Kim, C Lipchik, PG Gavin, G Yothers, ... Journal of Clinical Oncology, JCO. 23.01080, 2024 | 1 | 2024 |
| Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. X Lu, L Chen, Y Wang, C Cai, RS Kim, C Lipchik, D Fumagalli, G Yothers, ... Journal of Clinical Oncology 40 (16_suppl), 3607-3607, 2022 | 1 | 2022 |
| Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41 N Song, XE Tan, Y Wang, RS Kim, H Bandos, G Tang, E Mamounas, ... Cancer Research 81 (13_Supplement), 532-532, 2021 | 1 | 2021 |
| NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer SA Jacobs, Y Wang, J Abraham, H Feng, AJ Montero, C Lipchik, ... Breast Cancer Research 26 (1), 69, 2024 | | 2024 |
